ISI Thomson-Reuters has just released the latest Impact Factor numbers (2010 data). Amongst virology eponymous journals, Retrovirology (based on Impact Factor) now leads the pack. In the latest ranking, Retrovirology ranks at 443 out of 8005 journals indexed by ISI for Impact Factor. By comparison the Journal of Virology ranks at 454. Retrovirology’s Impact Factor and Immediacy Index are both slightly ahead of those for the Journal of Virology and well-ahead of Virology. The Retrovirology numbers also compare very favorably to two stalwarts of journal publishing, the Journal of Biological Chemistry and the Journal of Molecular Biology.
Next week 20 BioMed Central employees will be taking on Nature Publishing Group in a clash of the science publishing titans, in the form of 10K charity run through Regent’s Park in London.
BioMed Central set this challenge in a bid to raise funds for our partner charity, Computer Aid International, an IT charity which refurbishes old computer equipment for use in developing countries. You can support BMC by making a donation to Computer Aid http://bit.ly/dsuw94 All contributions will go towards the cost of supplying Kenyatta University in Kenya with a container of reconditioned computer equipment, where it is urgently needed.
I think this is a very worthwhile cause. I wouldn’t ask you to make a contribution if …
Last week, I had the opportunity to finally meet in person many of the folks at BMC. The realities of electronic publishing are that you are in constant contact with many people who you never see and have never met personally. On the occasion of the BMC award reception, I had the opportunity to meet some of the very capable staff who work with me daily in publishing Retrovirology. When the story of Open Access publishing is finally written, it will in part be a magical tale about BMC and these capable young people doing great things to change the face of publishing. I am immensely grateful and honored for the privilege of working with such outstanding individuals.
Ruth, Alison, Ed, Srimathy, …
Periodically, Retrovirology rotates a portion of its editorial board. We are delighted to welcome the following 7 new members to our board. They are Klaus Uberla (Germany), Juan Martin-Serrano (UK), Peter Cherepanov (UK), Carlos Brites (Brazil), Rob Gorelick (US), Shibo Jiang (US), and Rosemary Kiernan (France).
We wish to thank the wonderful services of the following departing editoral board members: Nafees Ahmad (US), David Brighty (UK), Warner Greene (US), Finn Skou Pedersen (Denmark), Roger Pomerantz (US), Leonid Margolis (US); and once again, we acknowldege the untimely passing of our board member David Derse (US).
This morning Maureen Shuh, a former post doctoral fellow with David Derse, wrote me to say "It is with great sadness that I inform you that Dr. David Derse passed away last night. He had advanced stage liver cancer which was not diagnosed until several weeks ago at which point it was too late. He did not suffer, and he was surrounded by his family."
David was a valued member of the Retrovirology editorial board; he was an esteemed colleague and a good friend. We will miss David very much. We plan to publish an obituary of David in Retrovirology soon.
The Retrovirology Prize alternates yearly between recognizing a non-HIV retrovirologist (2009 and odd years) and an HIV retrovirologist (2008 and even years). There can be some discretion on this guideline, exercised from time-to-time by the selection committee. Any individual can initiate a nomination of others or self-nominate. A nomination includes a statement (1000 words or less) of the nominee’s significant contributions to retrovirus research, a curriculum vitae of the nominee, and a statement by the nominator that the nominee has agreed to be nominated. The selection committee consists of the Editors of Retrovirology (currently, M. Benkirane, B. Berkhout, M. Fujii, K.T. Jeang, M. Lairmore, A. Lever, and M. Wainberg). All nominations submitted to the selection committee must be communicated through …
Charlotte Hubbard and Matt McKay represented Biomed Central at the Society of Chinese Bioscientists (SCBA) recent meeting in Taipei. Charlotte made a presentation to the SCBA on BMC’s publishing efforts with society journals.
Charlotte Hubbard (BMC), Kuan-Teh Jeang (Retrovirology), and Matt McKay (BMC) at the SCBA meeting.
The meeting was also attended by David Cyranoski, chief scientific correspondent at Nature’s Tokyo Bureau, and Dennis Normile, Science magazine’s Tokyo Bureau chief. Both David and Dennis appeared to be enjoying their experience in Taipei as they worked hard covering the SCBA meeting. You can also read Dennis’ blog of the meeting.
David Cyranoski (Nature) and Dennis Normile (Science) hard at work in Taipei.
The Journal Citation Report of 2008 Impact Factors for journals tracked by ISI Thomson was released this past Friday. Amongst the top four journals that primarily publish basic (as opposed to clinical) original virological research, J. Virol., Virology, and J. Gen. Virol. experienced small reductions in their 2008 impact factors. On the other hand, the Impact Factor of Retrovirology has remained steady despite publishing more papers in 2008 than 2007. Retrovirology is now a half point ahead of Virology, almost a full point ahead of J. Gen. Virol, and more than two points ahead of AIDS Research and Human Retroviruses. J. Virol. continues to lead the pack. Of note, Retrovirology remains the only journal out of the five journals listed in the table below that is …
Citations to Retrovirology articles have nearly doubled every year since 2005 for the past several years. The graph below from ISI illustrates this increasing trend. In 2008, Retrovirology published slightly more than 100 articles; in the same year Retrovirology papers were cited approximately 1,000 times. The journal continues to make excellent progress. Note that the data for 2009 are ongoing and represent only citations up to the month of April.
Retrovirology editorial board member Jean-Luc Darlix participated this past weekend to help raise 6.3 million Euros for AIDS research. Jean-Luc has been involved in SIDACTION since its founding. In the inset, he discusses his views on today’s HIV-1 research, the difficulties with the failed Merck vaccine study, and hopes for increased cooperation between research laboratories.